The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new real-time, personalized nutrition guidance SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, launches Meal Map, a new nutrient-categorization tool that combines AI-powered instant feedback with human care teams to help members in its cardiometabolic programs understand the nutrient quality of ...

Core Viewpoint - Omada Health, Inc. reported strong financial results for the second quarter of 2025, highlighting a 49% year-over-year revenue growth and significant member growth, indicating progress towards profitability [2][4]. Financial Performance - Revenue reached $61 million, representing a 49% increase compared to the second quarter of 2024 [8]. - Total members grew to 752,000, a 52% increase year-over-year [8]. - Gross margin improved to 66%, up from 60% in the same quarter of the previous year [9]. - Non-GAAP gross margin was 68%, compared to 63% in the second quarter of 2024 [9]. - The net loss narrowed to $5 million, down from a net loss of $11 million in the second quarter of 2024 [9]. - Adjusted EBITDA loss was $0.2 million, significantly improved from a loss of $6.8 million in the same quarter of 2024 [9]. Financial Outlook - For the year ending December 31, 2025, Omada expects revenue in the range of $235 million to $241 million [9]. - Adjusted EBITDA loss is projected to be between $9 million and $5 million [9]. Debt Management - On July 31, 2025, Omada fully repaid $31.0 million in principal and $0.4 million in accrued interest under its term loan facility and revolving line of credit, ahead of schedule [6]. Product and Service Development - The company has seen success with its GLP-1 companion programs, which are now available through two of the largest pharmacy benefit managers in the U.S. [8]. - In May, Omada introduced an AI-agent named OmadaSpark, aimed at providing real-time motivational interviewing and nutrition education to members [8]. Company Background - Omada Health is a virtual-first healthcare provider focused on chronic disease management, with over a decade of experience and a wide customer base exceeding 2,000 clients [11].

Core Viewpoint - The GLP-1 drug revolution continues to thrive in the first half of 2025, with Novo Nordisk's Wegovy and Eli Lilly's Zepbound emerging as star products, driving significant capital interest in the industry [2] Group 1: Omada Health - Omada Health, established in 2011, went public on June 6, 2025, at a price of $19 per share, raising approximately $150 million [3] - The stock surged to a high of $28 on its first day, closing at $23, marking a 21% increase and elevating the company's valuation to about $1.28 billion [3] - In 2024, Omada reported revenues of $169.8 million, a 38% year-over-year increase, with a gross margin of 60.6% [3] - By Q1 2025, revenues soared to $55 million, a 57% increase, while net losses decreased from $19 million to $9.4 million [3] - Omada's business model focuses on charging enterprises, health plans, and insurance channels for ongoing remote management services, filling the gap in health management between in-person visits [4] Group 2: Metsera - Metsera, founded in 2022, completed its IPO in January 2025 at $18 per share, raising $275 million [5] - The stock closed at $26.50 on its first day, reflecting a 47% increase, with an early high of over $35 [5] - Metsera's market capitalization was previously under $2 billion, but it is viewed as a strong contender in the anti-obesity sector [6] Group 3: Pipeline and Clinical Highlights - Metsera's lead product, MET-097i, is a long-acting GLP-1 receptor agonist showing promising results in early clinical trials, with an average weight loss of 11.3% over 12 weeks [7] - The drug demonstrates potential for monthly dosing, with a longer duration of action compared to competitors like Zepbound and Ozempic [7] - MET-233i, another product from Metsera, shows advantages in weight loss and pharmacokinetics, supporting monthly dosing [8] - Metsera's cash reserves post-IPO are approximately $590 million, ensuring operational sustainability until 2027 [9] Group 4: Industry Landscape - Other companies are also pursuing opportunities in the GLP-1 space, including Aardvark Therapeutics and BioAge Labs, which are building IPO frameworks and advancing their core pipelines [11][12] - The GLP-1 ecosystem is characterized by diverse technological pathways, providing investors with various options [14] Group 5: Investment Enthusiasm - The GLP-1 market is projected to exceed $100 billion by 2030, attracting significant investor interest [15] - Companies like Metsera and Omada are seen as having competitive advantages, such as long-acting formulations and extensive digital platforms [15] - Clinical milestones, such as Phase 3 trial initiations, are expected to act as catalysts for stock price increases [15]